Skip to main content

Illumina Secures $40M for Accelerator Startups

NEW YORK (GenomeWeb) – Illumina today announced that its startup accelerator has secured $40 million from Viking Global Investors to fund promising genomic firms.

Accelerator graduates that raise between $1 million and $5 million in new capital will receive additional dollar-for-dollar match funding from Illumina Accelerator Boost Capital.

"This capital commitment will be instrumental in driving value for our startups as they advance breakthrough applications in genomics," Amanda Cashin, head of Illumina Accelerator, said in a statement.

The Illumina Accelerator provides early-stage startups with a $100,000 seed investment, business guidance, access to Illumina's sequencing systems and reagents, and fully operational lab space in the San Francisco Bay Area for a six-month funding cycle. The program selected its inaugural class of three firms in October 2014, consisting of Encoded Genomics, EpiBiome, and Xcell Biosciences.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.